• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡格列净可阻碍糖尿病患者的缺血后肢恢复。

Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes.

机构信息

Department of Surgery, Section of Vascular Surgery, Washington University School of Medicine, St Louis, MO, USA.

Department of Medicine, Division of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine, St Louis, MO, USA.

出版信息

Vasc Med. 2021 Apr;26(2):131-138. doi: 10.1177/1358863X20961153. Epub 2020 Oct 23.

DOI:10.1177/1358863X20961153
PMID:33095685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8588833/
Abstract

There is a reported increased incidence of lower extremity amputations in individuals with diabetes who are treated with canagliflozin (an SGLT2 receptor inhibitor). It is unclear whether this is an unintended consequence of therapy, or whether canagliflozin can affect peripheral limb perfusion in the setting of underling arterial malperfusion. To evaluate this we explored the effect of canagliflozin on tissue recovery following unilateral hind-limb ischemia (HLI). Adult wildtype (+/+) and diabetic (db/db) mice were maintained on 8 weeks of a regular chow diet, or a chow diet containing canagliflozin (200 mg/kg). Following HLI, hind-limb appearance, function, and Doppler perfusion were serially evaluated. Gastrocnemius muscle fiber size and microvessel density were also evaluated 21 days following HLI. We observed that db/db that received a diet containing canagliflozin had significantly worse hind-limb function and appearance scores compared to both db/db mice that received a regular diet and +/+ mice that received a canagliflozin diet. At post-HLI day 21, db/db mice that received a canagliflozin diet also had decreased Doppler perfusion, gastrocnemius muscle fiber size, and microvessel density compared to +/+ mice that received a canagliflozin diet. These findings indicate that canagliflozin appears to impede ischemic peripheral tissue recovery and warrant further clinical investigation in individuals with diabetes and a history of peripheral artery disease.

摘要

有报道称,在接受卡格列净(一种 SGLT2 受体抑制剂)治疗的糖尿病患者中,下肢截肢的发病率增加。目前尚不清楚这是治疗的意外后果,还是卡格列净是否会影响潜在动脉功能不全情况下的外周肢体灌注。为了评估这一点,我们研究了卡格列净对单侧后肢缺血(HLI)后组织恢复的影响。成年野生型(+/+)和糖尿病(db/db)小鼠分别维持 8 周的普通饲料饮食或含卡格列净的饲料(200mg/kg)。HLI 后,连续评估后肢外观、功能和多普勒灌注情况。HLI 后 21 天还评估了比目鱼肌纤维大小和微血管密度。我们观察到,接受含卡格列净饮食的 db/db 小鼠的后肢功能和外观评分明显低于接受普通饮食的 db/db 小鼠和接受卡格列净饮食的+/+小鼠。在 HLI 后第 21 天,接受卡格列净饮食的 db/db 小鼠的多普勒灌注、比目鱼肌纤维大小和微血管密度也低于接受卡格列净饮食的+/+小鼠。这些发现表明,卡格列净似乎会阻碍缺血性周围组织的恢复,需要对有糖尿病和外周动脉疾病病史的个体进行进一步的临床研究。

相似文献

1
Canagliflozin impedes ischemic hind-limb recovery in the setting of diabetes.卡格列净可阻碍糖尿病患者的缺血后肢恢复。
Vasc Med. 2021 Apr;26(2):131-138. doi: 10.1177/1358863X20961153. Epub 2020 Oct 23.
2
Dysregulation of ghrelin in diabetes impairs the vascular reparative response to hindlimb ischemia in a mouse model; clinical relevance to peripheral artery disease.糖尿病中胃饥饿素的失调会损害小鼠模型后肢缺血的血管修复反应;对周围动脉疾病的临床相关性。
Sci Rep. 2020 Aug 12;10(1):13651. doi: 10.1038/s41598-020-70391-6.
3
Gene therapy with Pellino-1 improves perfusion and decreases tissue loss in Flk-1 heterozygous mice but fails in MAPKAP Kinase-2 knockout murine hind limb ischemia model.Pellino-1 基因治疗改善 Flk-1 杂合子小鼠的灌注并减少组织损失,但在 MAPKAP Kinase-2 敲除小鼠后肢缺血模型中失败。
Microvasc Res. 2022 May;141:104311. doi: 10.1016/j.mvr.2022.104311. Epub 2022 Jan 7.
4
Recovery from hind limb ischemia is less effective in type 2 than in type 1 diabetic mice: roles of endothelial nitric oxide synthase and endothelial progenitor cells.2型糖尿病小鼠后肢缺血的恢复效果不如1型糖尿病小鼠:内皮型一氧化氮合酶和内皮祖细胞的作用。
J Vasc Surg. 2009 Dec;50(6):1412-22. doi: 10.1016/j.jvs.2009.08.007. Epub 2009 Oct 17.
5
Trimetazidine ameliorates hindlimb ischaemic damage in type 2 diabetic mice.曲美他嗪可改善 2 型糖尿病小鼠的后肢缺血损伤。
Ann Med. 2021 Dec;53(1):1099-1107. doi: 10.1080/07853890.2021.1925147.
6
BAG3 Attenuates Ischemia-Induced Skeletal Muscle Necroptosis in Diabetic Experimental Peripheral Artery Disease.BAG3 减轻糖尿病实验性外周动脉疾病缺血诱导的骨骼肌坏死。
Int J Mol Sci. 2022 Sep 14;23(18):10715. doi: 10.3390/ijms231810715.
7
Development of a two-stage limb ischemia model to better simulate human peripheral artery disease.建立两阶段肢体缺血模型以更好地模拟人类外周动脉疾病。
Sci Rep. 2020 Feb 26;10(1):3449. doi: 10.1038/s41598-020-60352-4.
8
Resolvin D2 Enhances Postischemic Revascularization While Resolving Inflammation.消退素D2在解决炎症的同时增强缺血后血管再生。
Circulation. 2016 Aug 30;134(9):666-680. doi: 10.1161/CIRCULATIONAHA.116.021894. Epub 2016 Aug 9.
9
Type-2 diabetic Lepr(db/db) mice show a defective microvascular phenotype under basal conditions and an impaired response to angiogenesis gene therapy in the setting of limb ischemia.2型糖尿病Lepr(db/db)小鼠在基础条件下表现出微血管表型缺陷,并且在肢体缺血情况下对血管生成基因治疗的反应受损。
Front Biosci. 2007 Jan 1;12:2003-12. doi: 10.2741/2205.
10
Praliciguat Promotes Ischemic Leg Reperfusion in Leptin Receptor-Deficient Mice.普拉西呱促进瘦素受体缺陷小鼠的缺血性腿部再灌注。
Circ Res. 2023 Jan 6;132(1):34-48. doi: 10.1161/CIRCRESAHA.122.322033. Epub 2022 Nov 30.

引用本文的文献

1
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis.钠-葡萄糖协同转运蛋白2抑制剂与动脉粥样硬化
Am J Prev Cardiol. 2025 Jul 18;23:101061. doi: 10.1016/j.ajpc.2025.101061. eCollection 2025 Sep.
2
Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes.钠-葡萄糖协同转运蛋白 2 抑制剂:聚焦于除糖尿病以外对临床结局的有利影响。
Int J Mol Sci. 2022 Mar 4;23(5):2812. doi: 10.3390/ijms23052812.
3
Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling.

本文引用的文献

1
Time Trends in the Incidence of Long-Term Mortality in T2DM Patients Who Have Undergone a Lower Extremity Amputation. Results of a Descriptive and Retrospective Cohort Study.接受下肢截肢的2型糖尿病患者长期死亡率的时间趋势。一项描述性和回顾性队列研究的结果
J Clin Med. 2019 Oct 2;8(10):1597. doi: 10.3390/jcm8101597.
2
B lymphocytes expressing high levels of PD-L1 are key regulators of diabetes development in non-obese diabetic mice.高表达 PD-L1 的 B 淋巴细胞是非肥胖型糖尿病小鼠糖尿病发展的关键调节者。
Mol Immunol. 2019 Oct;114:289-298. doi: 10.1016/j.molimm.2019.07.026. Epub 2019 Aug 13.
3
Global vascular guidelines on the management of chronic limb-threatening ischemia.
钠-葡萄糖协同转运蛋白 2 抑制剂对血管细胞功能和动脉重塑的影响。
Int J Mol Sci. 2021 Aug 16;22(16):8786. doi: 10.3390/ijms22168786.
全球血管指南:慢性肢体威胁性缺血的管理。
J Vasc Surg. 2019 Jun;69(6S):3S-125S.e40. doi: 10.1016/j.jvs.2019.02.016. Epub 2019 May 28.
4
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂作用机制、代谢特征和血液动力学效应的综述。
Diabetes Obes Metab. 2019 Apr;21 Suppl 2:9-18. doi: 10.1111/dom.13650.
5
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation.卡格列净抑制人内皮细胞增殖和血管生成。
Front Pharmacol. 2019 Apr 16;10:362. doi: 10.3389/fphar.2019.00362. eCollection 2019.
6
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
7
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.卡格列净对 2 型糖尿病截肢风险的影响:CANVAS 项目。
Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.
8
SGLT-2 Inhibitors and Peripheral Artery Disease: A Statistical Hoax or Reality?SGLT-2 抑制剂与外周动脉疾病:统计学骗局还是现实?
Curr Probl Cardiol. 2019 Jul;44(7):207-222. doi: 10.1016/j.cpcardiol.2018.06.004. Epub 2018 Jul 6.
9
Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia.卡格列净可改善严重肢体缺血实验模型中的血流恢复情况。
JACC Basic Transl Sci. 2018 May 30;3(2):327-329. doi: 10.1016/j.jacbts.2018.01.010. eCollection 2018 Apr.
10
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.卡格列净可减轻 APOE 基因敲除小鼠动脉粥样硬化及炎症进程。
Cardiovasc Diabetol. 2018 Jul 26;17(1):106. doi: 10.1186/s12933-018-0749-1.